B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the Domain

New York, USA, May 31, 2023 (GLOBE NEWSWIRE) — B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the Domain

The prevalence of B-cell lymphoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of B-cell lymphoma and the growing research and development activities to develop novel therapies to treat B-cell lymphoma to drive the market. The companies developing the potential therapies in the last stage of development include ZAI Lab, Nektar Therapeutics, Oncternal Therapeutics, and several others.

DelveInsight’s ‘B-Cell Lymphoma Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline B-cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the B-cell lymphoma pipeline domain.

Key Takeaways from the B-Cell Lymphoma Pipeline Report

• DelveInsight’s B-cell lymphoma pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-cell lymphoma treatment. 
• Key B-cell lymphoma companies such as Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others are evaluating new B-cell lymphoma drugs to improve the treatment landscape.
• Promising B-cell lymphoma pipeline therapies such as Zilovertamab, Odronextamab, PF-07901801, Abexinostat, GNC-038, AUTO3, VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, Poseltinib, TQ-B3525, DPX-Survivac, THOR-707, Orelabrutinib, ALLO 501A, Prizloncabtagene autoleucel, Mosunetuzumab, Bifikafusp alfa, ALETA 001, Parsaclisib, ThisCART19A, CNCT-19, SHR-A1912, LP-168, TG-1801, Zanubrutinib, BGB-11417, BGB 16673,  ME-401, BGB-10188,  Tafasitamab, RG 6026, ALLO-647,  bbT369, Capivasertib, NKTR-255, Loncastuximab tesirine, GB-241, MK-2140, PCLX-001, ATG-008, CC-122, BZ019, LCAR-AIO,  and others are under different phases of B-cell lymphoma clinical trials.
• In May 2023, Bristol Myers Squibb announced positive topline results from two studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, an open-label, multicenter, pivotal Phase 1, single-arm study evaluating Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including mantle cell lymphoma (MCL). Results showed both studies met the primary endpoint of overall response rate, with Breyanzi demonstrating statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
• In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
• In May 2023, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy.
• In January 2023, Fate Therapeutics, Inc. announced that it had declined a proposal from Janssen Biotech, Inc. (“Janssen”) for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023.
• In December 2022, Biogen Inc. announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen has no payment obligations and received tiered royalties on potential net sales of glofitamab within the United States as part of the companies long-standing collaboration on antibodies targeting CD20.
• In November 2022, IGM Biosciences, Inc. and ADC Therapeutics SA announced that they have entered into a clinical trial collaboration and supply agreement to evaluate the combination of imvotamab, IGM’s novel IgM CD20 x CD3 T cell engaging bispecific antibody, and ZYNLONTA® (loncastuximab tesirine-lpyl), ADC Therapeutics’ CD19-directed antibody-drug conjugate (ADC), for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).

Request a sample and discover the recent advances in B-cell lymphoma treatment drugs @ B-Cell Lymphoma Pipeline Report

The B-cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage B-cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the B-cell lymphoma clinical trial landscape.

B-Cell Lymphoma Overview

B-cell Lymphoma is a type of cancer that develops in B cells. B-cell lymphomas can be indolent or aggressive. The majority of B-cell lymphomas are non-Hodgkin lymphomas. There are numerous subtypes of B-cell non-Hodgkin lymphoma. Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma are examples of these. The type and stage of cancer determine the prognosis and treatment. Patients might have other general B-cell lymphoma symptoms such as heavy sweating at night, high temperatures that come and go with no obvious cause, losing a lot of weight, and others. Doctors call this group of symptoms B symptoms. Some people may also have unexplained itching. 

A physical exam and blood work, followed by imaging studies, are the first steps in identifying B-cell lymphoma. Imaging tests for B-cell lymphoma diagnosis may include chest X-ray, computed tomography, and positron emission tomography. The aim of B-cell lymphoma treatment is to cure the lymphoma, control symptoms, stop lymphoma from spreading to other parts of the body, and stop lymphoma from coming back. There are various medication combinations. R-CHOP is a popular combination. Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone are examples of such medications.

Find out more about B-cell lymphoma treatment drugs @ Drugs for B-Cell Lymphoma Treatment

A snapshot of the B-Cell Lymphoma Pipeline Drugs mentioned in the report:

Learn more about the emerging B-cell lymphoma pipeline therapies @ B-Cell Lymphoma Clinical Trials

B-Cell Lymphoma Therapeutics Assessment

The B-cell lymphoma pipeline report proffers an integral view of the B-cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the B-Cell Lymphoma Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intravenous, Oral, Subcutaneous.
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, Bispecific antibody, Recombinant fusion protein, Small molecule, Gene Therapy, CAR-T cell therapy.
• Therapeutics Assessment By Mechanism of Action: Receptor tyrosine kinase-like orphan receptor antagonists, T lymphocyte stimulants, CD47 antigen inhibitors, Rad51 recombinase inhibitors, CD137 antigen agonists, T lymphocyte replacements, Exportin-1 protein inhibitors, Phosphatidylinositol 3 kinase delta inhibitors, Apoptosis stimulants; Myristoyl transferase inhibitors.
• Key B-Cell Lymphoma Companies: Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others
• Key B-Cell Lymphoma Pipeline Therapies:  Zilovertamab, Odronextamab, PF-07901801, Abexinostat, GNC-038, AUTO3, VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, Poseltinib, TQ-B3525, DPX-Survivac, THOR-707, Orelabrutinib, ALLO 501A, Prizloncabtagene autoleucel, Mosunetuzumab, Bifikafusp alfa, ALETA 001, Parsaclisib, ThisCART19A, CNCT-19, SHR-A1912, LP-168, TG-1801, Zanubrutinib, BGB-11417, BGB 16673,  ME-401, BGB-10188,  Tafasitamab, RG 6026, ALLO-647,  bbT369, Capivasertib, NKTR-255, Loncastuximab tesirine, GB-241, MK-2140, PCLX-001, ATG-008, CC-122, BZ019, LCAR-AIO, and others.

Dive deep into rich insights for new drugs for B-cell lymphoma treatment, visit @ B-Cell Lymphoma Drugs

Table of Contents

For further information on the B-cell lymphoma pipeline therapeutics, reach out @ B-Cell Lymphoma Treatment Drugs

Related Reports

B-Cell Lymphoma Epidemiology

B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends.

B-Cell Lymphoma Market

B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others.

Diffuse Large B-Cell Lymphoma Pipeline

Diffuse Large B-Cell Lymphoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others.

Diffuse Large B-Cell Lymphoma Market

Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others.

Diffuse Large B-Cell Lymphoma Epidemiology

Diffuse Large B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the DLBCL epidemiology trends.

Other Trending Reports

Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn